Physician profile
David M Macari
NPI 1992116123
$9,790.98
in general payments reported to CMS, 2019-2025
71 companies · $1,850 in 2025
The $1,850 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $245 · 2020: $384 · 2021: $748 · 2022: $1,358 · 2023: $1,427 · 2024: $3,779 · 2025: $1,850.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,902 · Consulting Fee: $2,025 · Travel and Lodging: $89.29 · Education: $40.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,901.60 |
| Consulting Fee | $2,025.00 |
| Travel and Lodging | $89.29 |
| Education | $40.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $2,494.65 | 2021-2025 | Rybrevant, Tecvayli, Erleada |
| Novartis Pharmaceuticals Corporation | $641.30 | 2019-2025 | |
| Celgene Corporation | $602.89 | 2020-2025 | Reblozyl, Pomalyst, Opdualag |
| Astrazeneca Pharmaceuticals LP | $516.84 | 2020-2025 | Enhertu, Lynparza, Imfinzi |
| Incyte Corporation | $348.32 | 2021-2025 | Jakafi, Monjuvi, Pemazyre |
| Amgen INC. | $286.66 | 2019-2023 | Nplate, Xgeva, Vectibix |
| Genentech USA, INC. | $267.14 | 2020-2025 | Tecentriq, Polivy, Phesgo |
| Astellas Pharma US INC | $233.95 | 2021-2025 | Xtandi, Padcev, Vyloy |
| Daiichi Sankyo INC. | $222.96 | 2022-2025 | Enhertu, Datroway |
| Pfizer INC. | $222.70 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $216.67 | 2020-2025 | Opdualag, Eliquis, Opdivo |
| Eisai INC. | $167.76 | 2019-2025 | |
| Beigene USA, INC. | $158.44 | 2021-2025 | Tevimbra, Brukinsa |
| Genzyme Corporation | $146.27 | 2020-2023 | |
| Abbvie INC. | $133.40 | 2023-2025 |
Show all 71 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Adaptive Biotechnologies Corporation | $132.60 | 2022-2024 | Clonoseq |
| Kite Pharma, INC. | $128.98 | 2019-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $128.77 | 2019-2025 | Fruzaqla |
| Aveo Pharmaceuticals, INC. | $120.54 | 2021-2025 | |
| Blueprint Medicines Corporation | $119.26 | 2020-2024 | Ayvakit |
| Seagen INC. | $116.96 | 2021-2023 | Tukysa, Padcev |
| G1 Therapeutics, INC. | $111.26 | 2022-2023 | Cosela |
| Karyopharm Therapeutics INC. | $110.16 | 2022-2025 | Xpovio |
| Bayer Healthcare Pharmaceuticals INC. | $101.84 | 2021-2025 | |
| Jazz Pharmaceuticals INC. | $98.93 | 2021-2023 | Zepzelca |
| Gilead Sciences, INC. | $94.68 | 2021-2025 | Trodelvy |
| Merck Sharp & Dohme LLC | $92.17 | 2020-2025 | Keytruda |
| Pharmacyclics LLC, An Abbvie Company | $84.02 | 2019-2023 | Imbruvica |
| Pharmaessentia USA Corporation | $82.76 | 2022-2025 | Besremi |
| Array Biopharma INC | $80.37 | 2020-2025 | Mektovi, Braftovi, Xalkori |
| Alexion Pharmaceuticals, INC. | $80.29 | 2021-2025 | Ultomiris |
| Sobi, INC | $74.64 | 2022-2024 | |
| Agios Pharmaceuticals, INC. | $69.11 | 2019-2025 | Pyrukynd |
| Sun Pharmaceutical Industries INC. | $64.85 | 2022-2025 | |
| Emd Serono, INC. | $64.77 | 2023-2024 | Tepmetko |
| Glaxosmithkline, LLC. | $58.38 | 2022-2025 | Ojjaara |
| Regeneron Healthcare Solutions, INC. | $57.09 | 2022-2024 | Libtayo |
| Azurity Pharmaceuticals, INC. | $55.37 | 2025 | Danziten |
| Rigel Pharmaceuticals, INC. | $52.69 | 2021-2025 | Rezlidhia, Tavalisse, Tavalisse |
| Novocure INC. | $52.65 | 2024-2025 | Optune Lua (Novottf-200t), Optune |
| Boehringer Ingelheim Pharmaceuticals, INC. | $52.61 | 2021-2022 | |
| Pharmacosmos Therapeutics INC. | $49.42 | 2024-2025 | Cosela, Monoferric |
| Tersera Therapeutics LLC | $48.42 | 2022-2024 | Xermelo, Zoladex |
| Dendreon Pharmaceuticals LLC | $45.50 | 2022-2025 | Provenge |
| Stemline Therapeutics INC. | $44.42 | 2024-2025 | Orserdu |
| Shield Therapeutics INC | $41.13 | 2023-2025 | Accrufer |
| Genmab U.S., INC. | $38.73 | 2023-2024 | Epkinly |
| Mirati Therapeutics, INC. | $38.67 | 2023 | Krazati |
| Lilly USA, LLC | $37.25 | 2020 | |
| Servier Pharmaceuticals LLC | $37.02 | 2022-2023 | |
| Morphosys, US INC. | $36.01 | 2022-2023 | Monjuvi |
| Recordati_rare_diseases_inc. | $35.87 | 2023-2024 | Sylvant |
| Exelixis INC. | $35.32 | 2022-2024 | Cabometyx |
| Puma Biotechnology, INC. | $30.65 | 2021-2025 | |
| Foundation Medicine, INC. | $30.17 | 2022-2023 | Foundationone Cdx |
| Lexicon Pharmaceuticals, INC. | $26.83 | 2020 | |
| Organon LLC | $23.47 | 2021-2022 | |
| Blue Earth Diagnostics | $22.58 | 2025 | Posluma |
| Tempus Ai, INC | $22.20 | 2024 | |
| Cti Biopharma Corp. | $20.16 | 2023 | Vonjo |
| Acrotech Biopharma INC. | $19.96 | 2024 | Beleodaq |
| Amag Pharmaceuticals, INC. | $19.28 | 2022 | |
| Taiho Oncology, INC. | $18.71 | 2023 | |
| Beone Medicines USA, INC. | $18.67 | 2025 | Tevimbra |
| Nestle Healthcare Nutrition INC. | $17.76 | 2023 | |
| Alnylam Pharmaceuticals INC. | $15.75 | 2022 | |
| Tolmar, INC. | $15.41 | 2025 | Rubraca |
| Pharmaand Gmbh | $15.41 | 2025 | Rubraca |
| Eusa Pharma (US) LLC | $14.60 | 2021 | |
| Deciphera Pharmaceuticals INC. | $14.16 | 2023 | Qinlock |
| Adc Therapeutics America, INC. | $11.75 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Macari listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.